Staphylococcus aureus

Phase I SBIR Grant Received to Develop Lipid-Based Vaccines

Published in Vaccine Weekly, September 20th, 2000

Aquila Biopharmaceuticals, Inc. (AQLA), Framingham, Massachusetts, announced that it has been awarded a grant from the U.S. National Institutes of Health (NIH) to support the development of novel vaccines to prevent Staphylococcus aureus infections based on the CD1 immune enhancement technology.

The grant was awarded to Aquila under Phase I of the Small Business Innovation Research (SBIR) Program of the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) branch of NIH.

"The SBIR grant for the development of a novel vaccine for S. aureus further validates our CD1 technology and the opportunities it opens for new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-09-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry